Business UpdateJun 1, 2026, 04:05 PM
EDAP TMS SA Rebrands as FocalTherics, Focuses on HIFU Growth
AI Summary
EDAP TMS SA, operating as FocalTherics, presented its strategic transformation into a high-growth, pure-play robotic focal therapy company at its Investor Day on June 1, 2026. The company is accelerating its HIFU business, projecting significant revenue growth and moving non-core segments to discontinued operations. Key initiatives include expanding the Focal One platform to new indications like BPH and Endometriosis, supported by favorable reimbursement and clinical evidence. EDAP TMS SA reiterated its financial guidance, emphasizing a pathway to profitability driven by its focused HIFU strategy.
Key Highlights
- EDAP TMS SA presented at the FocalTherics Investor Day on June 1, 2026, showcasing its transformation into a pure-play robotic focal therapy company.
- The company is focusing on accelerating growth in its HIFU (High-Intensity Focused Ultrasound) business, projecting revenue to reach $52M by CY26E.
- EDAP TMS SA plans to move its non-core ESWL and Distribution business to discontinued operations as of Q2 CY26.
- The company highlighted the expansion of its Focal One platform for Benign Prostatic Hyperplasia (BPH) and Endometriosis indications.
- Focal One system placements are projected to drive revenue growth, with a target of approximately 60% gross margin by CY26E.
- The company reiterated its CY26E HIFU-only revenue guidance of $50M-$54M, with a pathway to operating income breakeven in CY28.
Price Impact
More from EDAP